ST;
My point was not that this had failed but that it is competing in a different market segment - the warfarin segment. I agree though that the Arixtra market may well stabilise - more likely at around $450-500 million with the approval of the PE indication.
The last sales figures for Arixtra that I saw were for the first quarter '07. I would anticipate a 12-15% uplift on those figures which would give an annualised sales increment of 50-70%. I would anticipate a bigger rise once PE is approved in the US. I guess we will know soon but the trajectory is up.
- Forums
- ASX - By Stock
- competitors
TSN
the sustainable nutrition group ltd
Add to My Watchlist
0.00%
!
1.0¢

ST;My point was not that this had failed but that it is...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online